225 related articles for article (PubMed ID: 25261754)
1. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
Bordia T; McGregor M; Papke RL; Decker MW; McIntosh JM; Quik M
Exp Neurol; 2015 Jan; 263():277-84. PubMed ID: 25261754
[TBL] [Abstract][Full Text] [Related]
2. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
3. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
4. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Zhang D; McGregor M; Decker MW; Quik M
J Pharmacol Exp Ther; 2014 Oct; 351(1):25-32. PubMed ID: 25034405
[TBL] [Abstract][Full Text] [Related]
5. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Quik M; Campos C; Grady SR
Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
[TBL] [Abstract][Full Text] [Related]
6. Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).
Hudzik TJ; Basso AM; Lynch JJ; Bracken WM; Mohler EG; Kohlhaas KL; Xu H; Haig G; Gault L
Pharmacol Biochem Behav; 2017 Jul; 158():22-31. PubMed ID: 28579351
[TBL] [Abstract][Full Text] [Related]
7. Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Leino S; Kohtala S; Rantamäki T; Koski SK; Rannanpää S; Salminen O
BMC Neurosci; 2018 Nov; 19(1):77. PubMed ID: 30497382
[TBL] [Abstract][Full Text] [Related]
8. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Huang LZ; Parameswaran N; Bordia T; Michael McIntosh J; Quik M
J Neurochem; 2009 May; 109(3):826-37. PubMed ID: 19250334
[TBL] [Abstract][Full Text] [Related]
9. α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior.
Inden M; Takata K; Yanagisawa D; Ashihara E; Tooyama I; Shimohama S; Kitamura Y
Neurochem Int; 2016 Mar; 94():74-81. PubMed ID: 26911419
[TBL] [Abstract][Full Text] [Related]
10. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.
Lee AM; Arreola AC; Kimmey BA; Schmidt HD
Behav Brain Res; 2014 Nov; 274():168-75. PubMed ID: 25128791
[TBL] [Abstract][Full Text] [Related]
11. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.
Yohn NL; Turner JR; Blendy JA
J Pharmacol Exp Ther; 2014 May; 349(2):348-54. PubMed ID: 24627467
[TBL] [Abstract][Full Text] [Related]
12. Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors.
van Hout M; Klein J; Ahring PK; Brown DT; Thaneshwaran S; Dos Santos AB; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
Biochem Pharmacol; 2020 Apr; 174():113788. PubMed ID: 31887290
[TBL] [Abstract][Full Text] [Related]
13. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease.
Liu Y; Zeng X; Hui Y; Zhu C; Wu J; Taylor DH; Ji J; Fan W; Huang Z; Hu J
Neuropharmacology; 2015 Apr; 91():87-96. PubMed ID: 25486621
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
16. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
17. Characterization of AN317, a novel selective agonist of α6β2-containing nicotinic acetylcholine receptors.
Sandager-Nielsen K; Ahring PK; Klein J; van Hout M; Thaneshwaran S; Dos Santos AB; Jacobsen TA; Amrutkar DV; Peters D; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
Biochem Pharmacol; 2020 Apr; 174():113786. PubMed ID: 31887288
[TBL] [Abstract][Full Text] [Related]
18. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Suzuki S; Kawamata J; Matsushita T; Matsumura A; Hisahara S; Takata K; Kitamura Y; Kem W; Shimohama S
J Neurosci Res; 2013 Mar; 91(3):462-71. PubMed ID: 23239187
[TBL] [Abstract][Full Text] [Related]
19. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
[TBL] [Abstract][Full Text] [Related]
20. α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease.
Kawamata J; Suzuki S; Shimohama S
Curr Drug Targets; 2012 May; 13(5):623-30. PubMed ID: 22300030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
